Hardy J Rideout

List of Publications by Year
in descending order

41 papers	3,097 citations	236925 25 h-index	289244 40 g-index
43 all docs	43 docs citations	43 times ranked	3708 citing authors

#	Article	IF	Citations
1	Expression of A53T Mutant But Not Wild-Type Î±-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death. Journal of Neuroscience, 2001, 21, 9549-9560.	3.6	540
2	Pathological roles of Î±-synuclein in neurological disorders. Lancet Neurology, The, 2011, 10, 1015-1025.	10.2	328
3	Proteasomal inhibition leads to formation of ubiquitin/Î±â€synucleinâ€immunoreactive inclusions in PC12 cells. Journal of Neurochemistry, 2001, 78, 899-908.	3.9	253
4	LRRK2 Parkinson disease mutations enhance its microtubule association. Human Molecular Genetics, 2012, 21, 890-899.	2.9	177
5	Involvement of macroautophagy in the dissolution of neuronal inclusions. International Journal of Biochemistry and Cell Biology, 2004, 36, 2551-2562.	2.8	154
6	The Parkinson Disease Protein Leucine-Rich Repeat Kinase 2 Transduces Death Signals via Fas-Associated Protein with Death Domain and Caspase-8 in a Cellular Model of Neurodegeneration. Journal of Neuroscience, 2009, 29, 1011-1016.	3.6	147
7	Proteasomal Inhibition-Induced Inclusion Formation and Death in Cortical Neurons Require Transcription and Ubiquitination. Molecular and Cellular Neurosciences, 2002, 21, 223-238.	2.2	118
8	Cyclin-Dependent Kinase Activity Is Required for Apoptotic Death But Not Inclusion Formation in Cortical Neurons after Proteasomal Inhibition. Journal of Neuroscience, 2003, 23, 1237-1245.	3.6	107
9	Cyclin-Dependent Kinases and P53 Pathways Are Activated Independently and Mediate Bax Activation in Neurons after DNA Damage. Journal of Neuroscience, 2001, 21, 5017-5026.	3.6	100
10	The WD40 Domain Is Required for LRRK2 Neurotoxicity. PLoS ONE, 2009, 4, e8463.	2.5	100
11	Neurobiology of Î±-Synuclein. Molecular Neurobiology, 2004, 30, 001-022.	4.0	95
12	Mechanisms of Caspase-Independent Neuronal Death: Energy Depletion and Free Radical Generation. Journal of Neuroscience, 2003, 23, 11015-11025.	3.6	89
13	Synuclein-1 is selectively up-regulated in response to nerve growth factor treatment in PC12 cells. Journal of Neurochemistry, 2001, 76, 1165-1176.	3.9	80
14	Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not upâ€regulate iHSP70, following proteasomal inhibition. Journal of Neurochemistry, 2005, 93, 1304-1313.	3.9	74
15	The Neurobiology of LRRK2 and its Role in the Pathogenesis of Parkinsonâ€™s Disease. Neurochemical Research, 2014, 39, 576-592.	3.3	61
16	Nurr1:RXRÎ± heterodimer activation as monotherapy for Parkinsonâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3999-4004.	7.1	61
17	Application of proteasomal inhibitors to mouse sympathetic neurons activates the intrinsic apoptotic pathway. Journal of Neurochemistry, 2004, 90, 1511-1520.	3.9	50
18	Morphine enhancement of sucrose palatability: Analysis by the taste reactivity test. Pharmacology Biochemistry and Behavior, 1996, 53, 731-734.	2.9	49

#	Article	IF	Citations
19	Is spinal muscular atrophy a disease of the motor neurons only: pathogenesis and therapeutic implications?. Cellular and Molecular Life Sciences, 2016, 73, 1003-1020.	5.4	49
20	Î±-Synuclein Is Required for the Fibrillar Nature of Ubiquitinated Inclusions Induced by Proteasomal Inhibition in Primary Neurons. Journal of Biological Chemistry, 2004, 279, 46915-46920.	3.4	45
21	P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity. Biochemical Journal, 2018, 475, 1271-1293.	3.7	45
22	Lack of p53 delays apoptosis, but increases ubiquitinated inclusions, in proteasomal inhibitor-treated cultured cortical neurons. Molecular and Cellular Neurosciences, 2003, 24, 430-441.	2.2	43
23	Vitamin B12 modulates Parkinsonâ€™s disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection. Cell Research, 2019, 29, 313-329.	12.0	42
24	Regulation of Î±-synuclein by bFGF in cultured ventral midbrain dopaminergic neurons. Journal of Neurochemistry, 2003, 84, 803-813.	3.9	39
25	Reduced Mitochondrial Membrane Potential and Altered Responsiveness of a Mitochondrial Membrane Megachannel in p53-Induced Senescence. Biochemical and Biophysical Research Communications, 1999, 261, 123-130.	2.1	34
26	The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2020, 14, 865.	2.8	30
27	A motif within the armadillo repeat of Parkinsonâ€™s-linked LRRK2 interacts with FADD to hijack the extrinsic death pathway. Scientific Reports, 2018, 8, 3455.	3.3	24
28	Elevated In Vitro Kinase Activity in Peripheral Blood Mononuclear Cells of <scp>Leucineâ€Rich</scp> Repeat Kinase 2 <scp>G2019S</scp> Carriers: A Novel <scp>Enzymeâ€Linked</scp> Immunosorbent Assayâ€“Based Method. Movement Disorders, 2020, 35, 2095-2100.	3.9	24
29	Differential effects of Parkin and its mutants on protein aggregation, the ubiquitin-proteasome system, and neuronal cell death in human neuroblastoma cells. Journal of Neurochemistry, 2007, 102, 1292-1303.	3.9	21
30	Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes. Biochemical Journal, 2019, 476, 559-579.	3.7	19
31	The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinsonâ€™s Disease. Biomolecules, 2020, 10, 912.	4.0	18
32	Activation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations. PLoS ONE, 2016, 11, e0166053.	2.5	16
33	Allosteric Inhibition of Parkinsonâ€™s-Linked LRRK2 by Constrained Peptides. ACS Chemical Biology, 2021, 16, 2326-2338.	3.4	15
34	Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts. Npj Parkinson's Disease, 2022, 8, .	5.3	12
35	LRRK2 and the â€œLRRKtosomeâ€•at the Crossroads of Programmed Cell Death: Clues from RIP Kinase Relatives. Advances in Neurobiology, 2017, 14, 193-208.	1.8	9
36	Neuronal death signaling pathways triggered by mutant LRRK2. Biochemical Society Transactions, 2017, 45, 123-129.	3.4	8

#	Article	IF	Citations
37	A novel cell death pathway that is partially caspase dependent, but morphologically non-apoptotic, elicited by proteasomal inhibition of rat sympathetic neurons. Journal of Neurochemistry, 2008, 105, 653-665.	3.9	7
38	Targeted disruption of neuronal 19S proteasome subunits induces the formation of ubiquitinated inclusions in the absence of cell death. Journal of Neurochemistry, 2011, 119, 630-643.	3.9	7
39	Defining (and blocking) neuronal death in Parkinsonâ€™s disease: Does it matter what we call it?. Brain Research, 2021, 1771, 147639.	2.2	3
40	Insights into the Influence of Specific Splicing Events on the Structural Organization of LRRK2. International Journal of Molecular Sciences, 2018, 19, 2784.	4.1	2
41	Leucine rich repeat kinase 2 (<scp>LRRK2</scp>) peptide modulators: Recent advances and future directions. Peptide Science, 2022, 114, .	1.8	0